

## Plasma-based antigen persistence in the post-acute phase of SARS-CoV-2 infection

Michael J. Peluso<sup>1†\*</sup>, Zoe N. Swank<sup>2,3,4†</sup>, Sarah A. Goldberg<sup>5†</sup>, Scott Lu<sup>5</sup>, Thomas Dalhuisen<sup>5</sup>, Ella Borberg<sup>2,3,4</sup>, Yasmeen Senussi<sup>2,3,4</sup>, Michael A. Luna<sup>1</sup>, Celina Chang Song<sup>1</sup>, Alexis Clark<sup>1</sup>, Andhy Zamora<sup>1</sup>, Megan Lew<sup>1</sup>, Badri Viswanathan<sup>5</sup>, Beatrice Huang<sup>1</sup>, Khamal Anglin<sup>5</sup>, Rebecca Hoh<sup>1</sup>, Priscila Y. Hsue<sup>6</sup>, Matthew S. Durstenfeld<sup>6</sup>, Matthew A. Spinelli<sup>1</sup>, David V. Glidden<sup>5</sup>, Timothy J. Henrich<sup>7</sup>, J. Daniel Kelly<sup>5</sup>, Steven G. Deeks<sup>1</sup>, David R. Walt<sup>2,3,4‡</sup>, Jeffrey N. Martin<sup>5‡</sup>

<sup>1</sup> Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA

<sup>2</sup> Harvard Medical School, Boston, MA, USA

<sup>3</sup> Department of Pathology, Brigham & Women's Hospital, Boston, MA, USA

<sup>4</sup> Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA

<sup>5</sup> Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA

<sup>6</sup> Division of Cardiology, University of California, San Francisco, San Francisco, CA, USA

<sup>7</sup> Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA

†,‡, equal contribution

\* Corresponding Author: Michael J. Peluso  
Division of HIV, Infectious Diseases, and Global Medicine  
1001 Potrero Ave  
San Francisco, CA 94110  
415-476-4082 x 119  
[michael.peluso@ucsf.edu](mailto:michael.peluso@ucsf.edu)

Keywords: COVID-19, post-acute sequelae of SARS-CoV-2, Long COVID, viral persistence, antigen

1 **ABSTRACT**

2 BACKGROUND: Although RNA viruses like SARS-CoV-2 are generally thought to be transient, the  
3 persistence of viral components beyond the acute phase can be driven by a variety of virologic and  
4 immunologic factors. Recent studies have suggested that SARS-CoV-2 antigens may persist following  
5 COVID-19 but were limited by a lack of comparison to a large number of true negative control samples.

6  
7 METHODS: Using single molecule array (Simoa) assays for SARS-CoV-2 spike, S1, and nucleocapsid  
8 antigen in plasma from 171 pandemic-era individuals in the post-acute phase of SARS-CoV-2 infection and  
9 250 pre-pandemic control samples, we compared prevalence of antigen detection. We used logistic  
10 regression models and prevalence ratios (PRs) to assess the relationship between demographic and  
11 disease factors and antigen persistence.

12  
13 RESULTS: Compared to the proportion of antigen positivity in the pre-pandemic controls (2%), detection of  
14 any SARS-CoV-2 antigen was more frequent across all post-acute COVID-19 time bins (3-6 months:  
15 12.6%,  $p < 0.001$ ; 6-10 months, 10.7%,  $p = 0.0002$ ; 10-14 months, 7.5%,  $p = 0.017$ ). These differences were  
16 driven by spike protein for up to 14 months and nucleocapsid in the first 6 months after infection. The co-  
17 occurrence of multiple antigens at a single timepoint was uncommon. Hospitalization for acute COVID-19  
18 (versus not hospitalized) and worse self-reported health during acute COVID-19 among those not  
19 hospitalized (versus more benign illness) were associated with higher prevalence of post-acute antigen  
20 detection (PR 1.86,  $p = 0.03$ ; PR 3.5,  $p = 0.07$ , respectively) in the pandemic era.

21  
22 CONCLUSIONS: Our findings provide strong evidence that SARS-CoV-2 antigens can persist beyond the  
23 period of acute illness. The observation that more than 10% of plasma samples for over a year following  
24 initial SARS-CoV-2 infection contain detectable viral antigen, which are potentially immunogenic, has  
25 significant implications given the sheer number of people infected with SARS-CoV-2 to date. More work will

- 26 be needed to determine whether these antigens have a causal role in post-acute sequelae of SARS-CoV-2  
27 infection (PASC).

## 28 **BACKGROUND**

29 Components of certain RNA viruses may persist for weeks or months following acute infection.<sup>1</sup> Although  
30 such pathogens are generally thought to be transient, the persistence of viral components beyond the  
31 acute phase can be driven by a variety of virologic and immunologic factors. In some cases, persistence of  
32 active virus or viral antigens is associated with post-acute illness.<sup>2</sup>

33

34 Early in the pandemic, prolonged nasopharyngeal and/or gastrointestinal shedding of presumably non-  
35 infectious virus was observed in some individuals for 90 days or more, often despite clinical recovery.<sup>3,4</sup>  
36 More recently, evidence has suggested that SARS-CoV-2 protein and/or RNA can be detected beyond the  
37 acute phase of illness in a subset of individuals.<sup>5</sup> For example, viral RNA or protein persistence has since  
38 been identified in a variety of tissues in gut biopsy and autopsy studies for up to 2 years post-infection,  
39 although the clinical significance is unclear.<sup>6-9</sup> Recent studies assessing protein and RNA in plasma  
40 reported antigen detection in small cohorts of individuals post-COVID,<sup>10,11</sup> but their conclusions were limited  
41 by sporadic detection at or near the assay quantification limit and a lack of comparison to a large number of  
42 true negative control samples.

43

44 In this study, we first used a pre-pandemic sample cohort to determine the true false positive prevalence of  
45 the assay. We then measured the presence of SARS-CoV-2 antigen in plasma from a large, well-  
46 characterized cohort of persons in the post-acute phase of COVID-19 to determine whether antigen could  
47 be detected. We compared the prevalence after COVID-19 to that measured using plasma collected from  
48 true negative control participants prior to the emergence of SARS-CoV-2 infection. We hypothesized that  
49 the prevalence of antigen in plasma during the post-acute phase of COVID-19 would be significantly higher  
50 than in control specimens and would correlate with parameters such as illness severity during the acute  
51 phase of infection as well as clinical characteristics such as HIV infection status.

52

53

## 54 **METHODS**

### 55 *Overall Design*

56 In cross-sectional analyses, we compared participants in the post-acute phase of SARS-CoV-2 infection to  
57 persons studied prior to the COVID-19 pandemic for the presence of three different SARS-CoV-2 antigens  
58 in their plasma. Among the persons in the post-acute phase of SARS-CoV-2 infection, we also evaluated a  
59 variety of sociodemographic and clinical factors related to the acute phase of COVID-19 for their influence  
60 on SARS-CoV-2 antigen detection in the post-acute phase.

61

### 62 *Participants*

63 We studied two groups of participants. The first (hereafter known as pandemic-era) were participants in  
64 the University of California, San-Francisco (UCSF)-based Long-term Impact of Infection with Novel  
65 Coronavirus (LIINC) study (NCT04362150). Selection of participants into LIINC has been described  
66 previously.<sup>12</sup> Briefly, using facility- and community-based advertising, we enrolled (beginning in April 2020)  
67 consecutive adult volunteers who had earlier experienced their first episode of acute SARS-CoV-2 infection  
68 (confirmed by detection of SARS-CoV-2 RNA or antigen) and who were at least two weeks removed from  
69 their onset of COVID-19-related symptoms. Participants were examined at an initial study visit and every  
70 four months thereafter. For the present analysis, we sampled participants who had the greatest number of  
71 completed study visits (with stored plasma specimens) in the first 1.25 years following COVID-19 onset.  
72 The second group of participants (hereafter known as pre-pandemic-era) were from the UCSF-based  
73 Study of the Consequences of the Protease Era (SCOPE), an omnibus cohort study begun in 2001  
74 originally focused on investigation of the pathogenesis of HIV infection. It contains participants at variety of  
75 stages of HIV infection as well as ambulatory HIV-uninfected comparators, all of whom were volunteers  
76 from the community. For the present analysis, we randomly selected, among participants with stored  
77 plasma specimens prior to December 2019, four HIV-uninfected participants to every one HIV-infected  
78 participant, attempting to match the age and race/ethnicity distribution of the pandemic-era group. All  
79 participants provided written informed consent.

## 80 *Measurements*

81 Questionnaire-based. In both groups, interviewer-administered questionnaires collected data on  
82 sociodemographic and economic characteristics. In the pandemic-era group, we also inquired about  
83 details concerning the acute phase of SARS-CoV-2 infection, including symptoms experienced in the first 3  
84 weeks, self-reported worst perception of overall health on a 0 to 100 scale in the first 3 weeks, and whether  
85 hospitalization for COVID-19 occurred. The pandemic-era group also had all SARS-CoV-2 vaccinations  
86 recorded as well as any additional SARS-Co-V-2 infections since the initial infection.

87

88 Laboratory-based measurements. Peripheral blood was collected in EDTA-coated tubes and plasma  
89 stored at -80° C using similar procedures in both the pre-pandemic era and pandemic-era groups. Using  
90 once-thawed plasma, we employed single molecule array (Simoa) assays to measure SARS-CoV-2  
91 antigens from spike, S1, and nucleocapsid proteins; detailed methods have been described elsewhere.<sup>10,13</sup>  
92 Briefly, plasma samples were centrifuged at 2000 x g for 10 minutes at 4 °C and treated with 5 mM  
93 dithiothreitol (Pierce™ No-Weigh™ Format, Thermo Fisher Scientific) and protease inhibitors (Halt™  
94 Protease Inhibitor Cocktail, Thermo Fisher Scientific) for 15 minutes at 37° C. Each plasma sample was  
95 diluted 8-fold in a 96-well plate with Sample Diluent Buffer (Quanterix) and analyzed automatically with a  
96 three-step format on a HD-X Analyzer (Quanterix). In the first step, the plasma samples are incubated with  
97 antibody-coated magnetic beads. Assays for S1, spike, and nucleocapsid were performed separately,  
98 using antibodies against S1 (40150-D006, Sino Biological), S2 (MA5-35946, Invitrogen), and nucleocapsid  
99 (40143-R004, Sino Biological) conjugated to carboxylated magnetic beads (Quanterix). In the second step,  
100 the beads are resuspended in a solution of biotinylated detector antibodies. The same detector antibody  
101 against S1 is used for the S1 and spike assays (LT-1900, Leinco) and another antibody against  
102 nucleocapsid is used for the nucleocapsid assay (40143-R040, Sino Biological). In the third step, the beads  
103 are incubated in a solution of streptavidin conjugated  $\beta$ -galactosidase and lastly resuspended in a solution  
104 of resorufin  $\beta$ -D-galactopyranoside and loaded into a microwell array. The array is then sealed with oil and  
105 imaged. Average enzyme per bead (AEB) values are calculated by the HD-X Analyzer software thereafter

106 and converted to concentration values based on a calibration curve fit with a four-parameter logistic  
107 regression. Separately, the limit of detection (LOD) is calculated as the background AEB plus three times  
108 the standard deviation and converted to a concentration. Only values above the LOD are reported and  
109 values below the LOD are set to the LOD.

110

### 111 *Statistical analysis*

112 Up to 7 plasma timepoints (median 4, IQR 3-5) were assayed for SARS-CoV-2 antigens in the pandemic  
113 era group and one timepoint in the pre-pandemic group. In each plasma specimen tested, antigen  
114 detection was defined in four ways: a) presence or absence on each of three individual antigen assays;  
115 and b) presence of at least one of the three antigens (vs absence on all three). When comparing antigen  
116 prevalence in the pandemic-era group to the pre-pandemic era group, we defined three periods of time for  
117 the pandemic-era group: 3.0-6.0 months, 6.1-10.0 months, and 10.1-14 months post-onset of COVID-19  
118 symptoms. If there was more than one time point per person in a given time period, we chose the  
119 timepoint closest to the midpoint of the period. Comparison between groups were expressed with  
120 prevalence ratios and differences. All analyses were performed using Stata version 17.0 (StataCorp,  
121 College Station, Texas).

122

## 123 **RESULTS**

### 124 *Study participants*

125 We studied 171 pandemic-era participants over 660 timepoints between 0.9 and 15.4 months following  
126 initial SARS-CoV-2 symptom onset (Table 1). The pandemic-era group was 50% female, and median age  
127 was 46 years (IQR 37-57). The parent study was deliberately enriched for people with HIV (PWH); as a  
128 result, this comorbidity was relatively common in the study population (n=25, 15%). The pre-pandemic-era  
129 group (n=250) was similar in comparison, although included a lower proportion of women (22%).

130

### 131 *Antigen detection*

132 At least one SARS-CoV-2 antigen was detected in 5/250 (2%) pre-pandemic samples. In the pre-pandemic  
133 samples, spike was detected in 3/250 (1.2%) cases, S1 in 3/250 (1.2%) cases, and N in 2/250 (0.8%)  
134 cases. These values represent prevalence of false positivity. Of those with false positive detectable  
135 antigen, positive Spike values were: 83.46 pg/mL, 609.96 pg/mL, and 646.02 pg/mL; positive S1 values  
136 were: 34.67 pg/mL, 115.89 pg/mL, and 285.31 pg/mL; positive N values were: 649.28 pg/mL and 5716.32  
137 pg/mL.

138  
139 Compared to the proportion of antigen positivity in the pre-pandemic group, detection of any SARS-CoV-2  
140 antigen was more frequent across all pandemic-era time bins (Figure 1a; Supplemental Table 1). These  
141 differences were driven by spike protein for up to 14 months and nucleocapsid in the first 6 months after  
142 infection (Figure 1b-d).

143  
144 Of the 660 pandemic-era timepoints studied, 61 (9.2%) timepoints representing 25% of participants had  
145 one or more detectable SARS-CoV-2 antigens (Figure 2). The most commonly detected antigen was Spike  
146 (n=33, 5.0%), followed by S1 (n=15, 2.3%) and N (n=15, 2.3%). In most cases (59/61, 96.7%) only a single  
147 antigen was detected. The co-occurrence of multiple antigens at a single timepoint was uncommon. In  
148 2/61 cases (4.9%), two antigens were simultaneously detected (one case was positive for S1 and N; a  
149 second case was positive for Spike and N). In no case were all three antigens detected simultaneously. Of  
150 those with detectable antigen, the median Spike concentration was 27.7 pg/mL (IQR 20.5-33.7), median S1  
151 concentration was 31.2 pg/mL (IQR 20.5-193.0), and median N was 23.6 pg/mL (IQR 6.46-62.0).

152  
153 It was also uncommon for individuals to demonstrate the presence of antigen at multiple timepoints. Of 159  
154 participants who had multiple timepoints studied, 29 (18.2%) had antigen detected at a single post-acute  
155 timepoint, 10 (6.3%) had antigen detected at two post-acute timepoints, and one (0.63%) had antigen  
156 detected at three, four, and five post-acute timepoints, respectively (Figure 3). Most timepoints at which  
157 antigen was detected (51/61, 84%) occurred before the participant had ever received a SARS-CoV-2

158 vaccine (Figure 3). There were five instances in which antigen was detected within three weeks of a SARS-  
159 CoV-2 vaccine dose (three for S1, one for Spike, and one for N).

160

### 161 *Determinants of antigen positivity among pandemic-era participants*

162 Finally, we examined determinants of antigen detection among the pandemic-era participants. We found no  
163 strong evidence of an association between age, sex, race/ethnicity, HIV status, or body mass index (BMI)  
164 with antigen positivity. In contrast, we found strong evidence for an influence of severity of the acute phase  
165 of infection. As compared to those not hospitalized, participants who required hospitalization for acute  
166 COVID-19 were nearly twice as likely to have antigen detected (prevalence ratio [PR] 1.86,  $p=0.03$ ).  
167 Among those not hospitalized for COVID-19, those with the worst self-report of acute illness were over 3  
168 times as likely to have antigen detected as compared to those with the most benign self-reports (PR 3.5,  
169  $p=0.07$ ), an absolute difference of nearly 30%.

170

## 171 **DISCUSSION**

172 In comparison to pre-pandemic samples, we identified increased prevalence of SARS-CoV-2 antigen  
173 detection for up to 14 months following confirmed SARS-CoV-2 infection. This observation builds upon  
174 earlier work in smaller cohorts<sup>10,11</sup> and provides strong evidence that SARS-CoV-2 should be added to the  
175 list of RNA viruses whose components may persist beyond the period of acute illness.<sup>10</sup> Although a  
176 definitive link between antigen persistence and post-acute sequelae (e.g., Long COVID symptoms,  
177 cardiovascular disease, stroke, blood clots, etc.) has yet to be confirmed, the observation that more than  
178 10% of plasma samples for over a year following initial SARS-CoV-2 infection contain detectable viral  
179 antigens, which are potentially immunogenic,<sup>14-16</sup> has significant implications given the sheer number of  
180 people infected with SARS-CoV-2 to date.

181

182 Our study addresses two key criticisms of prior work evaluating SARS-CoV-2 antigen persistence.<sup>5</sup> First,  
183 our direct comparison with SARS-CoV-2 antigen signal measured in pre-pandemic control samples

184 mitigates the concern that antigen detection in the post-acute phase can be entirely explained by false-  
185 positive signal. Second, by including many specimens banked prior to the receipt of any SARS-CoV-2  
186 vaccine, we were able to determine that most antigen detection occurred in these pre-vaccine samples,  
187 suggesting that this finding is driven by SARS-CoV-2 infection and not prior vaccination (although one  
188 would not expect N protein to be present in relation to a SARS-CoV-2 vaccine).

189

190 The proportion of antigen positivity was lower in our study than in a prior report using this assay.<sup>10</sup> The  
191 lower prevalence detected in our study may be because we enrolled individuals in the post-acute phase  
192 regardless of illness severity or the presence of post-acute symptoms. In contrast, prior reports studied  
193 those seeking clinical care in Long COVID clinics, many of whom were highly symptomatic. Further work is  
194 needed to assess whether antigen persistence is a driver of the post-acute sequelae of SARS-CoV-2  
195 infection, or whether it is simply a remnant of prior infection with little or no consequences.

196

197 As in prior reports, we found antigen detection to be sporadic in individuals in whom it was present. It is  
198 possible that small variations over time could result in periods during which antigen is less detectable using  
199 current assays. Alternatively, antigen release from tissue reservoirs may in fact be intermittent, driven by  
200 host factors that have not yet been determined but might include differential release from tissues based on  
201 other factors such as the timing of a meal, hormonal factors, etc. The finding of an association between the  
202 severity of the acute phase illness and antigen detection in the post-acute phase also suggests that the  
203 burden of infectious antigen established early in the disease course may determine the likelihood of  
204 antigen persistence. This might offer one explanation for the protective effect of SARS-CoV-2 vaccination  
205 or antiviral therapy.<sup>17-20</sup> This finding also merits further investigation.

206

207 This study adds substantially to prior work that has challenged the framework that SARS-CoV-2 infection is  
208 transient in all cases.<sup>5</sup> The finding that the virus can evolve over months in immunocompromised  
209 individuals provides proof that persistent infection is possible.<sup>8</sup> Among immunocompetent individuals,

210 evolving B cell immunity provided early albeit indirect evidence that SARS-CoV-2 infection can be  
211 sustained.<sup>6</sup> More recently, an autopsy study showed widespread sub-genomic RNA in tissues of decedents  
212 up to 6 months post-COVID,<sup>7</sup> and we have reported SARS-CoV-2 spike RNA detection in gut biopsies for  
213 up to 2.5 years post-COVID.<sup>9</sup> SARS-CoV-2 antigens, particularly spike protein and its components, are  
214 known to be highly immunogenic.<sup>14-16</sup> These antigens have been shown to induce inflammatory cytokine  
215 responses as well as dysregulation of fibrinogen, complement proteins, and endothelial cells. Thus, the  
216 consistent identification of post-acute antigen in a subset of individuals following SARS-CoV-2 infection  
217 provides additional rationale for interventions meant to reduce or eliminate these antigens, either with  
218 antiviral drugs (if viral replication is present) or other drugs that could neutralize protein, clear infected cells,  
219 and/or modulate the immune response to these antigens (e.g., monoclonal antibodies). Such studies are  
220 now underway (NCT05877507, NCT05595369, NCT05576662, NCT05668091).

221

222 The strength of our analysis is the comparison to definitively negative pre-pandemic control specimens,  
223 demonstrating long-term antigen persistence in a small but significant proportion of individuals following  
224 COVID-19. However, the study has several limitations. The cohort was a convenience sample and not  
225 representative of all individuals experiencing SARS-CoV-2 infection during the period of interest. We  
226 studied samples preceding the emergence of the Omicron strains, and further work will be needed to  
227 assess the prevalence of antigen detection following infection with circulating SARS-CoV-2 variants. While  
228 our participants did not have known or clinically suspected reinfections prior to antigen detection, they were  
229 not systematically assessed for asymptomatic SARS-CoV-2 infection at each time point. Finally, even  
230 though the Simoa is highly sensitive, it is possible that more sensitive assays will be needed, particularly as  
231 the source of persistent SARS-CoV-2 antigen might not result in the production of a readily detectable  
232 systemic infection and many detected values were near the assay limit. Our team is developing such an  
233 assay (MOSAIC).<sup>21</sup>

234 In summary, we described post-acute antigen detection in a cohort of 171 individuals in the post-acute  
235 phase following SARS-CoV-2 infection. In comparison to pre-pandemic samples, we demonstrated an

236 increased prevalence of SARS-CoV-2 antigen detection for over 1 year following initial infection. While the  
237 overall prevalence of antigen detection was lower than in prior work comprising a different study  
238 population, this finding has major implications given the scale of the pandemic and the knowledge that  
239 SARS-CoV-2 spike protein is highly immunogenic. Taken together, these results provide strong evidence  
240 that SARS-CoV-2 antigen persists in the post-acute phase in some individuals. However, determination of  
241 whether antigen persistence is causally related to symptoms will require larger studies of carefully  
242 characterized samples, better delineating the test characteristics of these assays, and the use of  
243 experimental medicine to probe the biology of this mechanistic pathway.

244 **FOOTNOTES**

245 Acknowledgements

246 We are grateful to the study participants and their medical providers. We acknowledge current LIINC  
247 clinical study team members Grace Anderson, Kofi Asare, Melissa Buitrago, Alexis Clark, Emily Conway,  
248 Marin Ewing, Emily Fehrman, Tony Figueroa, Diana Flores, Marian Kerbleski, Megan Lew, Antonio  
249 Rodriguez, Justin Romero, Dylan Ryder, Matthew So, Viva Tai, Alex Tang, Meghann Williams, and Andhy  
250 Zamora; and current LIINC laboratory team members Amanda Buck, Brian LaFranchi, and David Maison.  
251 We thank Jessica Chen, Aidan Donovan, Carrie Forman, and Rania Ibrahim for assistance with data entry  
252 and review. We thank the UCSF AIDS Specimen Bank for processing specimens and maintaining the  
253 LIINC biospecimen repository. We are grateful to Elnaz Eilkhani and Monika Deswal for regulatory support.  
254 We also acknowledge all former LIINC team members.

255

256 Author Contributions

257 Designed the study: MJP, SGD, DRW, JNM

258 Designed the cohort: MJP, PYH, MSD, TJH, JDK, SGD, JNM

259 Collected biospecimens and clinical data: MJP, RH, ML, CCS, AC, AZ, ML, BH, KA.

260 Performed the assays: ZS, EB, YS in the laboratory of DRW.

261 Managed the data: SL, TD, BV.

262 Analyzed the data: MJP, SAG, DVG.

263 Wrote the manuscript: MJP, SGD, JDK, DRW, JNM.

264 Edited the manuscript: All authors.

265 Approved the manuscript: All authors.

266

267 Funding

268 This work was supported by funding from the PolyBio Research Foundation to support the LIINC Clinical  
269 Core, as well as support from NIH/NIAID 3R01AI141003-03S1, NIH/NIAID R01AI158013, and NIH/NIAID  
270 K23AI134327.

271

272 Conflicts of Interest

273 MJP reports consulting for Gilead Sciences and AstraZeneca, outside the submitted work. DRW has a  
274 financial interest in Quanterix Corporation, a company that develops an ultra-sensitive digital immunoassay  
275 platform. He is an inventor of the Simoa technology, a founder of the company, and also serves on its  
276 Board of Directors. Dr. Walt's interests were reviewed and are managed by Mass General Brigham and  
277 Harvard University in accordance with their conflict-of-interest policies.

## 278 REFERENCES

- 279 1. Griffin DE. Why does viral RNA sometimes persist after recovery from acute infections? *PLoS Biol*  
280 2022;20(6):e3001687. DOI: 10.1371/journal.pbio.3001687.
- 281 2. Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes. *Nature*  
282 *Medicine* 2022;28(5):911-923. DOI: 10.1038/s41591-022-01810-6.
- 283 3. Puhach O, Meyer B, Eckerle I. SARS-CoV-2 viral load and shedding kinetics. *Nature Reviews*  
284 *Microbiology* 2023;21(3):147-161. DOI: 10.1038/s41579-022-00822-w.
- 285 4. Owusu D, Pomeroy MA, Lewis NM, et al. Persistent SARS-CoV-2 RNA Shedding Without Evidence  
286 of Infectiousness: A Cohort Study of Individuals With COVID-19. *The Journal of Infectious Diseases*  
287 2021;224(8):1362-1371. DOI: 10.1093/infdis/jiab107.
- 288 5. Proal AD, VanElzakker MB, Aleman S, et al. SARS-CoV-2 reservoir in post-acute sequelae of  
289 COVID-19 (PASC). *Nat Immunol* 2023. DOI: 10.1038/s41590-023-01601-2.
- 290 6. Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2. *Nature*  
291 2021;591(7851):639-644. DOI: 10.1038/s41586-021-03207-w.
- 292 7. Stein SR, Ramelli SC, Grazioli A, et al. SARS-CoV-2 infection and persistence in the human body  
293 and brain at autopsy. *Nature* 2022;612(7941):758-763. DOI: 10.1038/s41586-022-05542-y.
- 294 8. Zollner A, Koch R, Jukic A, et al. Postacute COVID-19 is Characterized by Gut Viral Antigen  
295 Persistence in Inflammatory Bowel Diseases. *Gastroenterology* 2022;163(2):495-506 e8. DOI:  
296 10.1053/j.gastro.2022.04.037.
- 297 9. Peluso MJ, Ryder D, Flavell R, et al. Multimodal Molecular Imaging Reveals Tissue-Based T Cell  
298 Activation and Viral RNA Persistence for Up to 2 Years Following COVID-19. *medRxiv*  
299 2023:2023.07.27.23293177. DOI: 10.1101/2023.07.27.23293177.
- 300 10. Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, Walt DR. Persistent Circulating Severe  
301 Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus  
302 Disease 2019 Sequelae. *Clin Infect Dis* 2023;76(3):e487-e490. DOI: 10.1093/cid/ciac722.

- 303 11. Craddock V, Mahajan A, Spikes L, et al. Persistent circulation of soluble and extracellular vesicle-  
304 linked Spike protein in individuals with postacute sequelae of COVID-19. *J Med Virol*  
305 2023;95(2):e28568. DOI: 10.1002/jmv.28568.
- 306 12. Peluso MJ, Kelly JD, Lu S, et al. Persistence, Magnitude, and Patterns of Postacute Symptoms and  
307 Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for  
308 Measurement. *Open Forum Infect Dis* 2022;9(2):ofab640. DOI: 10.1093/ofid/ofab640.
- 309 13. Wu D, Milutinovic MD, Walt DR. Single molecule array (Simoa) assay with optimal antibody pairs for  
310 cytokine detection in human serum samples. *Analyst* 2015;140(18):6277-82. DOI:  
311 10.1039/c5an01238d.
- 312 14. Khan S, Shafiei MS, Longoria C, Schoggins JW, Savani RC, Zaki H. SARS-CoV-2 spike protein  
313 induces inflammation via TLR2-dependent activation of the NF- $\kappa$ B pathway. *Elife* 2021;10 (In eng).  
314 DOI: 10.7554/eLife.68563.
- 315 15. Ryu JK, Sozmen EG, Dixit K, et al. SARS-CoV-2 spike protein induces abnormal inflammatory  
316 blood clots neutralized by fibrin immunotherapy. *bioRxiv* 2021. DOI: 10.1101/2021.10.12.464152.
- 317 16. Liang S, Bao C, Yang Z, et al. SARS-CoV-2 spike protein induces IL-18-mediated cardiopulmonary  
318 inflammation via reduced mitophagy. *Signal Transduction and Targeted Therapy* 2023;8(1):108.  
319 DOI: 10.1038/s41392-023-01368-w.
- 320 17. Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. *Nature Medicine*  
321 2022;28(7):1461-1467. DOI: 10.1038/s41591-022-01840-0.
- 322 18. Azzolini E, Levi R, Sarti R, Pozzi C, Mollura M, Mantovani A, Rescigno M. Association Between  
323 BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health  
324 Care Workers. *JAMA* 2022. DOI: 10.1001/jama.2022.11691.
- 325 19. Xie Y, Choi T, Al-Aly Z. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study. *BMJ*  
326 2023;381:e074572. DOI: 10.1136/bmj-2022-074572.
- 327 20. Xie Y, Choi T, Al-Aly Z. Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19  
328 Condition. *JAMA Intern Med* 2023. DOI: 10.1001/jamainternmed.2023.0743.

- 329 21. Wu C, Dougan TJ, Walt DR. High-Throughput, High-Multiplex Digital Protein Detection with  
330 Attomolar Sensitivity. ACS Nano 2022;16(1):1025-1035. DOI: 10.1021/acsnano.1c08675.  
331

**Table 1.** Characteristics of study participants.

<b>Characteristic</b>	<b>Pandemic Era (n = 171)</b>	<b>Pre-pandemic Era (n = 250)</b>
<b>Age, years</b>	46 (37-57) <sup>a</sup> (19-85) <sup>b</sup>	48 (36-58) <sup>a</sup> (22-83) <sup>b</sup>
<b>Female Birth Sex</b>	86 (50%)	56 (22%)
<b>Sexual Orientation<sup>c</sup></b>		
Asexual	1 (0.6%)	0 (0.0%)
Bisexual	1 (0.6%)	24 (9.6%)
Gay/lesbian	34 (20%)	98 (39%)
Straight/heterosexual	110 (64%)	113 (45%)
Other	1 (0.6%)	0 (0%)
<b>Race/Ethnicity<sup>c</sup></b>		
Hispanic/Latino	47 (28%)	41 (16%)
White	92 (54%)	104 (42%)
Black/African American	8 (4.7%)	76 (30%)
Asian	17 (9.9%)	29 (12%)
Pacific Islander/Native Hawaiian	3 (1.8%)	0 (0.0%)
<b>Education<sup>c</sup></b>		
Any high school or less	33 (19%)	79 (32%)
Any college	69 (40%)	117 (47%)
Any graduate school	69 (40%)	52 (21%)
<b>Income<sup>c</sup></b>		
\$30,000 or less	24 (14%)	115 (46%)
\$30,001 to \$70,000	24 (14%)	36 (14%)
More than \$70,000	99 (58%)	40 (16%)
<b>Body Mass Index<sup>c</sup></b>		
Less than 18.5 kg/m <sup>2</sup>	2 (1.2%)	5 (2.0%)
18.5 kg/m <sup>2</sup> to 24.9 kg/m <sup>2</sup>	58 (34%)	116 (46%)
25.0 kg/m <sup>2</sup> to 29.9 kg/m <sup>2</sup>	49 (29%)	68 (27%)
More than 30.0 kg/m <sup>2</sup>	61 (36%)	50 (20%)
<b>HIV Seropositive<sup>c</sup></b>	25 (15%)	50 (20%)
<b>Hospitalized During Acute COVID Infection<sup>c</sup></b>	33 (19%)	N/A
<b>Symptom Count During Acute COVID Infection</b>	9 (6-12) <sup>a</sup> (0-25) <sup>b</sup>	N/A
<b>Health Score at Worst Point in COVID Illness<sup>c</sup></b>	45 (25-60) <sup>a</sup> (0-100) <sup>b</sup>	N/A
<b>Statement of Health<sup>c</sup></b>		
Excellent	N/A	62 (25%)
Very Good	N/A	82 (33%)
Good	N/A	65 (26%)
Fair	N/A	26 (10%)
Poor	N/A	3 (1.2%)

<sup>a</sup>Median (interquartile range)

<sup>b</sup>Absolute range

<sup>c</sup>Missing and nonresponse. Sexual orientation: 35 missing, 3 questioning/unsure, 1 prefer not to answer; race/ethnicity: 4 missing; education: 2 missing; income: 3 missing, 80 prefer not to answer; BMI: 12 missing; hospitalization: 1 missing; health score: 82 missing; statement of health: 12 missing

**Table 2.** Association between sociodemographic and clinical characteristics and antigen positivity.

Characteristic	Prevalence	Prevalence Ratio (95% CI)	Prevalence Difference (95% CI)	p-value
<b>Age, years</b>				
Less than 40	0.26	Ref	Ref	
40-65	0.21	0.81 (0.45 to 1.44)	-0.05 (-0.19 to 0.09)	0.47
65 or more	0.40	1.52 (0.71 to 3.25)	0.14 (-0.14 to 0.41)	0.31
<b>Sex</b>				
Female	0.20	Ref	Ref	
Male	0.29	1.49 (0.87 to 2.55)	0.10 (-0.03 to 0.23)	0.15
<b>Race/ethnicity</b>				
White	0.23	Ref	Ref	
Hispanic/Latino	0.32	1.40 (0.80 to 2.46)	0.09 (-0.07 to 0.25)	0.25
Black/African American	0.25	1.10 (0.31 to 3.87)	0.02 (-0.29 to 0.33)	0.89
Asian	0.18	0.77 (0.26 to 2.32)	-0.05 (-0.25 to 0.15)	0.64
Pacific Islander/Native Hawaiian	0.33	1.46 (0.28 to 7.59)	0.11 (-0.44 to 0.65)	0.68
<b>HIV</b>				
No	0.25	Ref	Ref	
Yes	0.24	0.97 (0.46 to 2.07)	-0.01 (-0.19 to 0.18)	0.94
<b>Body Mass Index<sup>a</sup></b>				
Less than 18.5 kg/m <sup>2</sup>	-	-	-	-
18.5 kg/m <sup>2</sup> to 24.9 kg/m <sup>2</sup>	0.21	Ref	Ref	
25.0 kg/m <sup>2</sup> to 29.9 kg/m <sup>2</sup>	0.29	1.38 (0.70 to 2.71)	0.08 (-0.09 to 0.24)	0.35
More than 30.0 kg/m <sup>2</sup>	0.26	1.27 (0.66 to 2.45)	0.06 (-0.10 to 0.21)	0.48
<b>Hospitalized During Acute COVID Infection</b>				
No	0.21	Ref	Ref	
Yes	0.39	1.86 (1.09 to 3.17)	0.18 (0.00 to 0.36)	0.03
<b>Symptom Count During Acute COVID Infection<sup>b,c</sup></b>				
0-5 symptoms	0.23	Ref	Ref	
6-8 symptoms	0.19	0.86 (0.34 to 2.19)	-0.03 (-0.23 to 0.17)	0.75
9-11 symptoms	0.10	0.46 (0.13 to 1.61)	-0.12 (-0.31 to 0.06)	0.22
12+ symptoms	0.29	1.27 (0.56 to 2.85)	0.06 (-0.14 to 0.26)	0.57
<b>Health Score at Worst Point in COVID Infection<sup>b,d</sup></b>				
>60	0.12	Ref	Ref	
50-60	0.13	1.11 (0.21 to 5.99)	0.01 (-0.19 to 0.22)	0.90
30-49	0.20	1.70 (0.35 to 8.25)	0.08 (-0.15 to 0.32)	0.51
<30	0.41	3.50 (0.84 to 14.6)	0.29 (0.01 to 0.58)	0.07


<sup>a</sup>Individuals whose BMI was <18.5 kg/m<sup>2</sup> (N=2) were omitted from the analyses due to collinearity

<sup>b</sup>Analyses only conducted amongst participants who were not hospitalized during their acute COVID infection


<sup>c</sup>N= 138

<sup>d</sup>N= 77


**Figure 1.** (a) Prevalence of SARS-CoV-2 antigen in plasma in the post-acute phase of COVID-19 in comparison to prevalence of false positivity in pre-pandemic control plasma. (b) Spike antigen prevalence. (c) Nucleocapsid antigen presence. (d) S1 presence. P-values represent Chi-square and Fisher's 2-sided exact test as appropriate.



**Figure 2.** Plasma antigen measurements. Dashed lines indicate limit of quantification for each analyte. Y-axis refers to log-transformed concentration, units are pg/mL.



**Figure 3.** Antigen measurements over time in pandemic-era participants with at least one positive antigen. Blue indicates spike, green nucleocapsid, and red S1. Horizontal dotted lines represent the assay limit of detection for each antigen. Vertical dotted lines indicate timing of any SARS-CoV-2 vaccine relative to antigen.



## Supplemental Table 1.

### Any SARS-CoV-2 Antigen

Group	No. of participants	No. of antigen positive (%)	Prevalence difference; 95% CI; p value
Pre-pandemic	250	5 (2.00%)	Reference
3 to 6.0 months after infection	151	19 (12.58%)	0.1058 (0.0502 to 0.1615; p-value < 0.001)
6 to 10.0 months	131	14 (10.69%)	0.0869 (0.0312 to 0.1425; p-value = 0.0002)
10 to 14 months*	122	9 (7.38%)	0.0538 (0.0042 to 0.0103; p-value = 0.017)

\*Fisher's 2-sided exact-test

### Spike\*

Group	No. of participants	No. of antigen positive (%)	Prevalence difference; 95% CI; p value
Pre-pandemic	250	3 (1.20%)	Reference
3 to 6.0 months after infection	151	9 (5.96%)	0.0476 (0.0075 to 0.0877; p-value = 0.012)
6 to 10.0 months	131	7 (5.34%)	0.0414 (0.0006 to 0.0822; p-value = 0.036)
10 to 14 months	122	5 (4.10%)	0.0289 (-0.0087 to 0.0667; p-value = 0.12)

\*Fisher's 2-sided exact-test

### N\*

Group	No. of participants	No. of antigen positive (%)	Prevalence difference; 95% CI; p value
Pre-pandemic	250	2 (0.80%)	Reference
3 to 6.0 months after infection	151	7 (4.64%)	0.0384 (0.0031 to 0.0737; p-value = 0.030)
6 to 10.0 months	131	3 (2.29%)	0.0149 (-0.0130 to 0.0428; p-value = 0.34)
10 to 14 months	122	2 (1.64%)	0.0084 (-0.0167 to 0.0335; p-value = 0.60)

\*Fisher's 2-sided exact-test

### S1\*

Group	No. of participants	No. of antigen positive (%)	Prevalence difference; 95% CI; p value
Pre-pandemic	250	3 (1.20%)	Reference
3 to 6.0 months after infection	151	4 (2.65%)	0.0145 (-0.0145 to 0.0434; p-value = 0.43)
6 to 10.0 months	131	4 (3.05%)	0.0185 (-0.0139 to 0.0509; p-value = 0.24)
10 to 14 months	122	3 (2.46%)	0.0126 (-0.0180 to 0.0432; p-value = 0.40)

\*Fisher's 2-sided exact-test

Supplemental Table 2a. Association between sociodemographic characteristics and ever S1 antigen positivity

Characteristic	Prevalence	Prevalence Ratio (95% CI)	Prevalence Difference (95% CI)	p-value
<b>Age, years</b>				
Less than 40	0.05	Ref	Ref	
40-65	0.04	0.77 (0.18 to 3.32)	-0.01 (-0.08 to 0.06)	0.72
65 or more	0.27	5.07 (1.26 to 20.3)	0.21 (-0.02 to 0.45)	0.02
<b>Sex</b>				
Female	0.05	Ref	Ref	
Male	0.08	1.77 (0.54 to 5.85)	0.04 (-0.04 to 0.11)	0.35
<b>Race/ethnicity<sup>a</sup></b>				
White	0.08	Ref	Ref	
Hispanic/Latino	0.06	0.84 (0.23 to 3.11)	-0.01 (-0.10 to 0.08)	0.79
Black/African American	-	-	-	-
Asian	0.06	0.77 (0.10 to 5.93)	-0.02 (-0.14 to 0.11)	0.80
Pacific Islander/Native Hawaiian	-	-	-	-
<b>HIV</b>				
No	0.07	Ref	Ref	
Yes	0.04	0.58 (0.08 to 4.39)	-0.03 (-0.12 to 0.06)	0.60
<b>Body Mass Index<sup>a</sup></b>				
Less than 18.5 kg/m <sup>2</sup>	-	-	-	-
18.5 kg/m <sup>2</sup> to 24.9 kg/m <sup>2</sup>	0.12	Ref	Ref	
25.0 kg/m <sup>2</sup> to 29.9 kg/m <sup>2</sup>	0.04	0.34 (0.07 to 1.56)	-0.08 (-0.18 to 0.02)	0.16
More than 30.0 kg/m <sup>2</sup>	0.03	0.27 (0.06 to 1.26)	-0.09 (-0.18 to 0.01)	0.09
<b>Hospitalized During Acute COVID Infection</b>				
No	0.06	Ref	Ref	
Yes	0.09	1.56 (0.43 to 5.57)	0.03 (-0.07 to 0.14)	0.50
<b>Symptom Count During Acute COVID Infection<sup>b</sup></b>				
0-5 symptoms	0.10	Ref	Ref	
6-8 symptoms	0.06	0.57 (0.10 to 3.24)	-0.04 (-0.17 to 0.09)	0.53
9-11 symptoms	0.03	0.36 (0.04 to 3.26)	-0.06 (-0.19 to 0.06)	0.36
12+ symptoms	0.05	0.49 (0.09 to 2.79)	-0.05 (-0.17 to 0.07)	0.42
<b>Health Score at Worst Point in COVID Illness<sup>a,b</sup></b>				
>60	0.06	Ref	Ref	
50-60	0.09	1.48 (0.14 to 15.3)	0.03 (-0.13 to 0.19)	0.74
30-49	0.15	2.55 (0.29 to 22.7)	0.09 (-0.10 to 0.29)	0.39
<30	-	-	-	-

<sup>a</sup>Individuals who are Black/African American (N=8) or Pacific Islander/Native Hawaiian (N=3), whose BMI was <18.5 kg/m<sup>2</sup> (N=2), or whose health score was <30 (N=17) were omitted from the analyses due to collinearity

<sup>b</sup>Analyses only conducted amongst participants who were not hospitalized during their acute COVID infection

<sup>c</sup>N= 138

<sup>d</sup>N= 60

Supplemental Table 2b. Association between sociodemographic characteristics and ever spike antigen positivity

Characteristic	Prevalence	Prevalence Ratio (95% CI)	Prevalence Difference (95% CI)	p-value
<b>Age, years</b>				
Less than 40	0.18	Ref	Ref	
40-65	0.13	0.75 (0.35 to 1.60)	-0.04 (-0.16 to 0.08)	0.46
65 or more	0.20	1.14 (0.36 to 3.64)	0.02 (-0.20 to 0.25)	0.83
<b>Sex</b>				
Female	0.13	Ref	Ref	
Male	0.18	1.38 (0.67 to 2.83)	0.05 (-0.06 to 0.16)	0.38
<b>Race/ethnicity<sup>a</sup></b>				
White	0.15	Ref	Ref	
Hispanic/Latino	0.19	1.26 (0.59 to 2.70)	0.04 (-0.10 to 0.17)	0.56
Black/African American	0.25	1.64 (0.45 to 6.01)	0.10 (-0.21 to 0.41)	0.48
Asian	0.06	0.39 (0.05 to 2.77)	-0.09 (-0.23 to 0.04)	0.33
Pacific Islander/Native Hawaiian	-	-	-	-
<b>HIV</b>				
No	0.15	Ref	Ref	
Yes	0.16	1.06 (0.40 to 2.83)	0.01 (-0.15 to 0.16)	0.90
<b>Body Mass Index<sup>a</sup></b>				
Less than 18.5 kg/m <sup>2</sup>	-	-	-	-
18.5 kg/m <sup>2</sup> to 24.9 kg/m <sup>2</sup>	0.09	Ref	Ref	
25.0 kg/m <sup>2</sup> to 29.9 kg/m <sup>2</sup>	0.20	2.37 (0.86 to 6.48)	0.12 (-0.02 to 0.25)	0.09
More than 30.0 kg/m <sup>2</sup>	0.18	2.09 (0.77 to 5.67)	0.09 (-0.03 to 0.22)	0.14
<b>Hospitalized During Acute COVID Infection</b>				
No	0.15	Ref	Ref	
Yes	0.15	0.99 (0.40 to 2.43)	-0.00 (-0.14 to 0.14)	0.98
<b>Symptom Count During Acute COVID Infection<sup>b,c</sup></b>				
0-5 symptoms	0.16	Ref	Ref	
6-8 symptoms	0.14	0.86 (0.27 to 2.71)	-0.02 (-0.19 to 0.15)	0.80
9-11 symptoms	0.07	0.43 (0.09 to 2.05)	-0.09 (-0.25 to 0.07)	0.28
12+ symptoms	0.21	1.33 (0.49 to 3.59)	0.05 (-0.13 to 0.23)	0.57
<b>Health Score at Worst Point in COVID Illness<sup>b,d</sup></b>				
>60	0.12	Ref	Ref	
50-60	0.09	0.74 (0.11 to 4.79)	-0.03 (-0.22 to 0.16)	0.75
30-49	0.05	0.43 (0.04 to 4.35)	-0.07 (-0.25 to 0.11)	0.47
<30	0.35	3.00 (0.70 to 12.9)	0.24 (-0.04 to 0.51)	0.12

<sup>a</sup>Individuals who are Pacific Islander/Native Hawaiian (N=3) or whose BMI was <18.5 kg/m<sup>2</sup> (N=2) were omitted from the analyses due to collinearity

<sup>b</sup>Analyses only conducted amongst participants who were not hospitalized during their acute COVID infection

<sup>c</sup>N= 138

<sup>d</sup>N= 77

Supplemental Table 2c. Association between sociodemographic characteristics and ever N antigen positivity

Characteristic	Prevalence	Prevalence Ratio (95% CI)	Prevalence Difference (95% CI)	p-value
<b>Age, years</b>				
Less than 40	0.05	Ref	Ref	
40-65	0.07	1.34 (0.36 to 5.01)	0.02 (-0.06 to 0.10)	0.66
65 or more	-	-	-	-
<b>Sex</b>				
Female	0.05	Ref	Ref	
Male	0.07	1.52 (0.44 to 5.21)	0.02 (-0.05 to 0.09)	0.51
<b>Race/ethnicity</b>				
White	0.02	Ref	Ref	
Hispanic/Latino	0.11	4.89 (0.98 to 24.4)	0.08 (-0.01 to 0.18)	0.05
Black/African American	0.13	5.75 (0.58 to 57.1)	0.10 (-0.13 to 0.34)	0.15
Asian	0.06	2.71 (0.26 to 28.4)	0.04 (-0.08 to 0.15)	0.41
Pacific Islander/Native Hawaiian	0.33	15.3 (1.85 to 127)	0.31 (-0.22 to 0.85)	0.03
<b>HIV</b>				
No	0.05	Ref	Ref	
Yes	0.08	1.46 (0.33 to 6.51)	0.03 (-0.09 to 0.14)	0.62
<b>Body Mass Index<sup>a</sup></b>				
Less than 18.5 kg/m <sup>2</sup>	-	-	-	-
18.5 kg/m <sup>2</sup> to 24.9 kg/m <sup>2</sup>	0.05	Ref	Ref	
25.0 kg/m <sup>2</sup> to 29.9 kg/m <sup>2</sup>	0.04	0.79 (0.14 to 4.56)	-0.01 (-0.09 to 0.07)	0.79
More than 30.0 kg/m <sup>2</sup>	0.08	1.58 (0.39 to 6.36)	0.03 (-0.06 to 0.12)	0.51
<b>Hospitalized During Acute COVID Infection</b>				
No	0.02	Ref	Ref	
Yes	0.21	9.69 (2.64 to 35.6)	0.19 (0.05 to 0.33)	<0.001
<b>Symptom Count During Acute COVID Infection<sup>b</sup></b>				
0-5 symptoms	-	-	-	-
6-8 symptoms	-	-	-	-
9-11 symptoms	-	-	-	-
12+ symptoms	-	-	-	-
<b>Health Score at Worst Point in COVID Illness<sup>b</sup></b>				
>60	-	-	-	-
50-60	-	-	-	-
30-49	-	-	-	-
<30	-	-	-	-

<sup>a</sup>Individuals who were 65 years or older (N=15) or whose BMI was <18.5 kg/m<sup>2</sup> (N=2) were omitted from the analyses due to collinearity

<sup>b</sup>Analyses were omitted due to complete collinearity